AMA Corporation Plc ("the Company") is domiciled in the United Kingdom. The Company’s registered office is located in London. The consolidated financial statements comprise those of the Company and its subsidiaries (together referred to as "the Group").
The Group is a software developer and systems integrator for collaborative work, providing advanced, highly-secure remote solutions for connected devices. The Group’s XpertEye suite provides augmented reality, dynamic workflow management, and dynamic online scheduling and planning. Combined with smart glasses or other camera sources (endoscope, microscope, dermatoscope, etc.), these innovative solutions enable experts and on-site technicians to share data and knowledge in real time, making remote support easier and more effective for users. They meet an increasing need for smart workplace transformation in companies seeking to boost productivity and competitiveness in a wide range of areas such as remote support, training, testing and healthcare.
These IFRS condensed consolidated interim financial statements for the 6-month period ending on June 30, 2026 have been approved by the Board of the Company on November 06, 2026.
2. Basis for preparation
2.1. Statement of compliance
These condensed consolidated interim financial statements for the 6-month period ending on June 30, 2026, have been prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the European Union (EU) and should be read in conjunction with the latest Company’s annual financial statements for the year ending on December 31, 2025, of the Company (the "latest annual financial statements").
They do not include all the information required for a complete set of financial statements prepared under IFRS. They do, however, include selected notes explaining significant events and transactions in order to understand the changes in the Company's financial position and performance since the last annual financial statements.
The accounting policies used to prepare these unaudited interim condensed consolidated financial statements are identical to those applied by the Group as of December 31, 2025, except for:
texts whose application is compulsory as from January 1, 2026;
the specific provisions of IAS 34 used in the preparation of the interim financial statements. The following amendments, which are mandatory for annual reporting periods beginning on or after January 1, 2026, have been applied by the Group:
Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures – Amendments to the Classification and Measurement of Financial Instruments;
Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures – Contracts Referencing Nature-dependent Electricity.
The standards and interpretations not yet mandatory as of June 30, 2026 are the following:
IFRS 18 Presentation and Disclosure in Financial Statements, whose application is for annual reporting periods beginning on or after January 1, 2027 (not yet approved by the EU);
IFRS 19 Subsidiaries without Public Accountability: Disclosures, whose application is for annual reporting periods beginning on or after January 1, 2027 (not yet approved by the EU), and
Amendments to IAS 21 – Translation to a Hyperinflationary Presentation Currency (issued by the IASB on 13 November 2025)
These texts have not been early adopted. The expected impacts are not considered significant, except for IFRS 18, for which the Group has not completed its assessment to date.
2.2. Cash position and financial situation
As at June 30, 2026, the Group's cash position stood at €1.2 million, compared with €2.1 million at December 31, 2025. Operating cash flows amounted to €1.5 million over the first half. The Group's net cash/(debt) position stood at €(0.2) million, compared with €0.4 million at the end of December 2025. AMA benefited from a €1 million waiver of shareholder current account debt by its principal shareholder, Guillemot Brothers SAS.
To date, AMA has €9.8 million in undrawn bank credit facilities guaranteed by Guillemot Brothers SAS, totalling four credit lines, with two currently being renewed.
2.3. Use of judgments and estimates
In preparing these condensed interim financial statements, management has made judgments and estimates that affect the application of the Company's accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual values may differ from estimated values.
2.4. Functional and presentation currency
The consolidated financial statements are presented in euros, which is the Company’s functional currency. All amounts have been rounded to the nearest thousand, unless otherwise indicated.
2.5. Seasonality of operations
The Group is not subject to significant seasonal fluctuations. The Group activity is linked to the progress of our clients' projects, which are not connected to seasonal events but depend on the internal schedules of each client.
A shareholder loan was granted by Guillemot Brothers SAS for €1,000k on March 13, 2026. The loan was later fully waived on March 31, 2026.
In February 2026, the €300k provision related to the AMF settlement was confirmed. . As the amount and the payment schedule are now fixed, the related provision has been reversed and the obligation recognised as a liability
AMA Xperteye Ltd HK, 85%-owned by the Group, entered liquidation proceedings in March 2026, resulting in its removal from the scope of consolidation. This transaction is part of the Group’s restructuring strategy and had no material impact on the Group’s consolidated financial position.
AMA XpertEye Ltd HK, 85%-owned by the Group, was liquidated on May 15, 2026, resulting in its removal from the scope of consolidation. The related equity and consolidation adjustments were therefore fully derecognized as of June 30, 2026.
AMA Xperteye Shanghai, 100%-owned by the Group, adopted a dissolution resolution on April 24, 2026. The deregistration process is ongoing and is expected to be completed by the end of
2026. The company remains fully consolidated as at June 30, 2026
Stock option plans: Two plans remain in force (Plan 2022 revised in January 2024 at €0.21, and Plan 2023 revised in February 2025 at €0.17 with a supplementary allocation of 667,000 options). No significant event occurred on the stock option plans during the period (no new revision, grant, exercise, or forfeiture).
In 2025 − A shareholder loan was granted by Guillemot Brothers SAS for €2,000k on June 27, 2025 and for €129k on December 31, 2025. These two loans were later fully waived on the same date. − As part of the continuation of the global savings plan launched in 2024, severance costs amounting to €507k were recorded in 2025;
− An administrative settlement agreement was concluded with the Financial Markets Authority for an amount of €300k concerning the financial investigation opened in 2022.
This agreement does not constitute an admission of guilt and does not represent a sanction; − In March 2023, the Company established a stock option plan that represented 3% of AMA's share capital at the time. These stock options had a six-year lifespan and were exercisable at a price of €0.35 two years after their issuance, contingent upon meeting a condition of ongoing employment. The vesting period ends on 27 March 2025, and the option exercise period runs until 26 March 2029.
− In February 2025, the Board of Directors, acting in accordance with section 16.2 of the plan, ratified a revision of the stock options' pricing and approved the grant of additional stock options.
− This adjustment involved issuing new options to supersede the original ones, aimed at maintaining their motivational value by lowering the exercise price from €0.35 to €0.17. This pricing revision affected 794,000 stock options, which accounted for 1.49% of AMA's share capital. The supplementary allocation covers 667,000 options, corresponding to 1.25% of the share capital. The financial impact recognized in the first quarter under IFRS 2 for this revision is approximately €41k.
− In January 2025, AMA Corporation Plc's owned 89,11% Romanian subsidiary, AMA Xperteye SRL, underwent liquidation. In March 2025, the liquidation process was also initiated for AMA Xperteye K.K., located in Japan, and AMA Xperteye Ltd HK, located in Hong Kong both 85% owned by AMA Corporation Plc. These actions were undertaken as part
As announced on October 1, 2026, AMA has initiated a significant adjustment to its organisation, involving the elimination of 8 positions in France. Upon completion, the Group will retain a team of 11 employees in France, across R&D, sales, customer support and corporate functions, together with 4 employees in its subsidiaries in the United States and Germany.
This reorganisation forms part of a broader cost reduction plan also targeting external expenses, including premises, IT infrastructure and software tools, outsourced services, and travel and operating costs.
The cost associated with this reorganisation is estimated at approximately €400k. Upon completion, annualised payroll costs are expected to decrease from approximately €2.1 million to €1.45 million, representing annual savings of approximately €650k. These savings will be supplemented by reductions in external costs.
The Group’s chief operating decision maker refers to the members of the Executive Committee and the Board of Directors.
The Group comprises four distribution subsidiaries, covering three geographic areas corresponding to the following segments:
Europe, which includes subsidiaries in France and Germany, and which primarily invoice customers in Europe;
North America, which includes subsidiary in the United States and which primarily invoice customers in the North American area;
Asia, which includes subsidiaries in Shanghai and which primarily invoice customers in the Asia area.
The subsidiaries in each geographic area correspond to operating segments with similar economic characteristics.
All of the subsidiaries offer similar products and services but are strategically monitored by geographic area.
Information relating to each operating segment is presented below. Operating income and adjusted EBITDA for each segment are used to measure performance as management considers that this information is the most relevant for understanding the earnings of each segment compared with earnings from other entities. Adjusted EBITDA is defined as operating income plus depreciation, amortisation and impairment of property, plant and equipment and intangible assets, share-based payment expenses, and other non-current expenses/income.
The other items in the income statement, including financial income and expenses as well as taxes, are included within “Registered office, support functions and intragroup”.
The "Cost of Sales" in the income statement is equal to the sum of "Merchandise purchases" and "Change in inventories" (included in the Profit margin in the segment information table below) and "Inventory impairment" (excluded from the Profit margin).
Other depreciation of property, plant and equipment and intangible assets (56) (19) (6) (232) (312) Other non-current expenses (138) (0) (1) (71) (210)
Intersector* 60 119 52 (231) -
Current operating loss 49 3 18 (2 811) (2 741)
Other non-current expenses - - - (136) (136)
Other non-current income - - - - -
Non-current operating loss - - - (136) (136)
Depreciation of property, plant and equipment and intangible assets 56 19 6 233 314
Changes in contract liabilities (prepaid income) is split as follows:
7.2. Other income
Other income breaks down as follows:
Other operating income decreased from €94k in June 2025 to €16k in June 2026, mainly due to the absence of operating grants in 2026 and a €48k decrease in other operating income. 2026.06 2025.06 € 000 € 000
Software & support services 554 694
Equipment sales 129 377
Pilot contracts 2 2
XpertEye solution revenue 685 1 073
Other services 64 105
Total revenue 748 1 178
2026.06 2025.06 € 000 € 000
Contract liabilities at 1 January 850 1 018
Increase in amounts received, net of revenue recognised for the period 354 561
Revenue recognised for the period included in opening amount (418) (541)
Cost of sales decreased from €435k in June 2025 to €149k in June 2026, mainly due to a shift in the revenue mix towards software, with lower equipment sales and purchases. Inventory impairment expenses also decreased. Cost of sales represented 20% of revenue, compared with 37% in June 2025.
Other purchases and external expenses decreased significantly from €1,271k to €496k, mainly driven by the continued impact of the Group’s cost-saving plan. In particular, general sub-contracting costs decreased from €651k to €157k, while employee benefits decreased from €1,785k to €1,222k following the Group’s restructuring measures and reduction in headcount.
Unlike in 2025, no share-based payment adjustment was recognized during the six-month period ended June 30, 2026. In 2025, a share-based payment expense had been recorded following the repricing of the stock option plan and the grant of additional stock options. No similar transaction or adjustment was identified during the first half of 2026 and, consequently, no additional share-based payment expense was recognized as of June 30, 2026.
7.5. Non-current operating income and expenses
On June 30 2025, Non-current operating expenses relates to the Group restructuring plan for €136 k.
On June 30 2026, there are no non-recurring expenses to be recognized
Group financial income and expense is split as follows:
9. Taxation
The income tax expense is determined based on the pre-tax profit for the interim period multiplied by management's best estimate of the weighted average annual tax rate expected for the full year. This rate is adjusted for the tax effect of certain items fully recognized in the period. Accordingly, the effective tax rate in the interim financial statements may differ from management's estimate of the effective tax rate in the annual financial statements.
2026.06 2025.06 € 000 € 000
Interest expense on loans and lease liability (49) (63)
Earnings attributable to holders of ordinary shares (basic):
Weighted average number of ordinary shares (basic and diluted):
Weighted average number of ordinary shares (diluted) at June 30, 2026 does not include the outstanding stock options.
Indeed, as the result of continuing operations is a loss, instruments giving deferred rights to capital such as stock options have an anti-dilutive effect. They are therefore not considered, and basic earnings per share are therefore identical to diluted earnings per share.
2026.06 2025.06 € 000 € 000
Net earnings attributable to owners of the Company (1 389) (2 888)
Net earnings attributable to holders of ordinary shares (1 389) (2 888)
2026.06 2025.06
Ordinary shares at 1 January 53 537 145 53 227 045
Capital increase 263 000
Weighted average number of ordinary shares at 31 December 53 537 145 53 490 045 Basic earnings per share in € (0,03) (0,05)